Allan L. Shaw
Allan L. Shaw is a four-time public company CFO (e.g., Serono & Syndax) and has served on five public boards, which included the chairing of two audit and two compensation committees. He currently serves on the board of directors of Vivus Inc. and is involved with a portfolio of healthcare activities. Prior, Shaw served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group.
ARTICLES BY ALLAN L. SHAW
-
![Common Chronic Diseases - Allan Shaw_450x300]( "Common Chronic Diseases: What Can Orphan Drugs Teach Us?")
Common Chronic Diseases: What Can Orphan Drugs Teach Us?4/1/2019What needs to be done to encourage the allocation of resources to develop/commercialize drugs for common chronic diseases because of the expense and risk of developing them?
-
![05_0116_DeeperDive_pic]( "Can You Afford To Take Biopharma Innovation For Granted?")
Can You Afford To Take Biopharma Innovation For Granted?1/1/2016When considered on a macro level, why should the U.S. subsidization of global medicine be any different from other U.S. global leadership roles (underwritten by U.S. taxpayers)?
-
![06_DeeperDive]( "Is Biopharma Consumerism The Center of Commercial Innovation?")
Is Biopharma Consumerism The Center of Commercial Innovation?12/1/2015As the patient-consumer becomes more educated and savvy, they will inevitably start to push back concerning the discrepancies in U.S.- versus international-branded drug pricing.
-
![05_1115_DeeperDive_pic]( "Why A Seasoned Management Team Is The Ultimate Competitive Advantage")
Why A Seasoned Management Team Is The Ultimate Competitive Advantage11/1/2015Given the choice, I would choose the combination of a mediocre asset and a great management team over a great asset and a mediocre management team. Simply put, management teams can create or destroy value.
-
![AllanShaw]( "Do Outcomes In Healthcare Matter When There Is Chronic Misalignment?")
Do Outcomes In Healthcare Matter When There Is Chronic Misalignment?10/1/2015“It is ironic that a longstanding fringe benefit such as medical insurance could actually serve as an antithesis to an optimal patient care system focused on outcomes and system savings.”
-
![05_0915_DeeperDive_pic]( "It’s A Competitive Sport: Coming To Terms With Bio-Mania")
It’s A Competitive Sport: Coming To Terms With Bio-Mania9/1/2015“It was not too long ago that the surge valuations of multibillion-dollar biotech deals were negatively received by the capital markets.”
-
![05_0815_DeeperDive_pic]( "Warning: Don’t Let Bio-Euphoria Distract You From Being Disciplined")
Warning: Don’t Let Bio-Euphoria Distract You From Being Disciplined8/1/2015“Innovation should go well beyond the science and apply to all aspects of an organization’s operations.”
-
![05_0715_DeeperDive_pic]( "Value & Pricing: Moving Past The Rhetoric In Biopharma")
Value & Pricing: Moving Past The Rhetoric In Biopharma7/1/2015Today we bear witness to a “golden age” for biopharmaceuticals. With all of the exciting/ innovative science, growing scripts, increase in drug approvals, and record revenue, it’s difficult to call it anything else.
-
![05_0615_DeeperDive_pic]( "Biomarkets: Looking For The Hole In The Donut")
Biomarkets: Looking For The Hole In The Donut5/27/2015The capital market IPO drought of 2008 to 2012 seems like a distant memory — funny how more than 120 IPOs can make us forget such a painful period. Furthermore, the strength of the biopharma sector has been buoyed by the stellar performance of large cap stocks driven by exciting product launches and impressive clinical data. Not since 2000 has the industry experienced such relevance and broadened interest, as evidenced by the investor cash inflows.
